The gut microbiome and its interaction with health, disease, treatment response and toxicity in patients advanced cancer: focus on lung cancer and immunotherapy
Affiliation
The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2020
Metadata
Show full item recordAbstract
NoneCitation
Tinsley N, Cook N. The gut microbiome and its interaction with health, disease, treatment response and toxicity in patients advanced cancer: focus on lung cancer and immunotherapy. Transl Lung Cancer Res. 2020;9(6):2305-7.Journal
Translational Lung Cancer ResearchDOI
10.21037/tlcr-20-407PubMed ID
33489792Additional Links
https://dx.doi.org/10.21037/tlcr-20-407Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.21037/tlcr-20-407
Scopus Count
Collections
Related articles
- Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
- Authors: Chau J, Yadav M, Liu B, Furqan M, Dai Q, Shahi S, Gupta A, Mercer KN, Eastman E, Hejleh TA, Chan C, Weiner GJ, Cherwin C, Lee STM, Zhong C, Mangalam A, Zhang J
- Issue date: 2021 Jul 13
- The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
- Authors: Oh B, Boyle F, Pavlakis N, Clarke S, Eade T, Hruby G, Lamoury G, Carroll S, Morgia M, Kneebone A, Stevens M, Liu W, Corless B, Molloy M, Kong B, Libermann T, Rosenthal D, Back M
- Issue date: 2021 Sep 27
- Gut microbiome and cancer immunotherapy.
- Authors: Sun JY, Yin TL, Zhou J, Xu J, Lu XJ
- Issue date: 2020 May
- Gut Microbiome and the Response to Immunotherapy in Cancer.
- Authors: Stancu AL
- Issue date: 2018 Sep 30
- Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
- Authors: Mao J, Wang D, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, Li Y, Sun H, Xue J, Song Y, Zuo B, Zhang J, Bian J, Zhang T, Yang X, Zhang L, Sang X, Zhao H
- Issue date: 2021 Dec